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“There is no such thing as absolute value in this world. You can only estimate 
what a thing is worth to you.” 
 
Charles Dudley Warner (1829-1900) 
American essayist and novelist 
. An evaluation of pharmacist-conducted medication reviews in home-dwelling Australians 
Andrew Stafford BPharm(Hons) MPS AACPA . Page V 
 
Acknowledgements 
I’d imagine that virtually everyone who has seen a PhD through to completion would 
appreciate that it’s not a solo effort, and I’m definitely no exception. Without the 
support, guidance, friendship and love (where appropriate) of the following people, 
I’m certain that this document would have never been completed: 
 Dr Peter Tenni: who has influenced so much of my life as a pharmacist, a 
researcher and an educator; I owe most of the success and pleasure my career 
has provided me with to your teaching and guidance; 
 Professor Gregory Peterson: for his supervision, insight and tireless work 
ethic. I could not have wished for a more inspirational mentor to introduce me 
to research; 
 Dr Ivan Bindoff: whose intelligence and critical thinking always made me view 
my research with new perspectives; 
 Leanne Chalmers: my brilliant sister, who has taught me more than anyone 
else about pharmacy practice, research and statistics, but never made me look 
(too) foolish whilst doing so;  
 Professor Chris Doran: who sowed the seeds for the utilities work, and taught 
me more about health economics than I could have ever learned otherwise;  
 Mum and Dad: despite being thousands of miles away, you were always there 
for me when I needed you; and, of course, 
 Dr Katherine Creeper: for believing in me, even when I didn’t. 
 
  
. An evaluation of pharmacist-conducted medication reviews in home-dwelling Australians 
Andrew Stafford BPharm(Hons) MPS AACPA . Page VI 
 
List of Publications 
Peer-reviewed journal publications 
Stafford A, Bindoff I, Tenni P, Peterson G, Doran C. A methodological framework for 
estimating the clinical and economic value of community pharmacists’ clinical 
interventions using expert opinion. J Clin Pharm Ther 2011:[in press]. 
Conference abstracts (oral) 
Stafford A. The top ten interventions in HMRs: What works and what doesn’t? AACP’s 
6th annual consultant pharmacy clinical seminar, 29-31 May 2010, The Hotel Grand 
Chancellor, Hobart, Tasmania. 
Stafford A, Tenni P, Peterson G, Doran C, Kelly W. The economic value of Home 
Medicines Reviews. Pharmacy Practice Research Summit 2010, 2-4 March 2010, 
Rydges Lakeside, Canberra, Australian Capital Territory, pp. 19. 
Stafford A, Tenni P, Peterson G, Doran C, Kelly W. Home Medicines Reviews - what are 
the most valuable interventions? Working together to bridge the gaps in disease 
management. 3-4 September 2010, Grand Hyatt, Melbourne, Victoria, pp. 32-33. 
Stafford A, Tenni P, Peterson G. The VALMER study (the Value of Medication Reviews) 
- what are common drug-related problems, and how do pharmacists resolve them? 
AACPs 5th annual consultant pharmacy clinical seminar, 28-31 May 2009, Sanctuary 
Cove, Queensland.  
Conference abstracts (poster) 
Stafford A, Tenni P, Peterson G, Doran C, Kelly W. Home Medications Reviews: The 
most common drug-related problems. Pharmacy Practice Research Summit 2010, 2-4 
March 2010, Rydges Lakeside, Canberra, Australian Capital Territory, pp. 19. 
Stafford A, Tenni P, Peterson G, Doran C, Kelly W. Home Medicines Reviews - what are 
the most common drug-related problems? Out of the Wilderness - 2009 APSA Annual 
. An evaluation of pharmacist-conducted medication reviews in home-dwelling Australians 
Andrew Stafford BPharm(Hons) MPS AACPA . Page VII 
 
Conference, 9-11 December 2009, Wrest Point Convention Centre, Hobart, Tasmania, 
pp. 167.  
. An evaluation of pharmacist-conducted medication reviews in home-dwelling Australians 
Andrew Stafford BPharm(Hons) MPS AACPA . Page VIII 
 
Abbreviations 
AACP Australian Association of Consultant Pharmacy  MAI Medication Appropriateness Index 
ABDI Australian Burden of Disease and Injury MBS Medicare Benefits Schedule 
ACE Angiotensin Converting Enzyme  MCQ Multiple-Choice Question 
ADE Adverse Drug Event MCS Microscopy Culture and Sensitivity 
ADR Adverse Drug Reaction MDC Major Diagnostic Criteria  
ALOS Average Length of Stay  MMA Medicare Modernisation Act  
AR-DRG Australian Refined Diagnosis Related Group  MMR Medication Management Review 
ASCEPT Australasian Society of Clinical and 
Experimental Pharmacologists and 
Toxicologists 
MRP Medication-Related Problems  
ATC Anatomic Therapeutic Chemical  MTM Medication Therapy Management 
BCPS Certification as a Pharmacotherapy Specialist  MTP Medication-Therapy Problems 
BEACH Bettering the Evaluation and Care of Health  MUR Medicines Use Reviews 
CBA Cost-Benefit Analysis  NHS National Health Service  
CCA Cost-Consequence Analysis  NICE National Institute for Clinical Excellence  
CEA Cost-Effectiveness Analysis  NPS National Prescribing Service 
CEAC Cost-Effectiveness Acceptability Curve NSAID Non-Steroidal Anti-Inflammatory Drugs 
CGP Certification as a Geriatric Pharmacy Specialist  PBS Pharmaceutical Benefits Scheme  
CI Clinical Intervention PCI Pharmaceutical Care Issues  
CMA Cost Minimisation Analysis  PhARIA Pharmacy Accessibility/Remoteness Index of 
Australia  
CMPMMP Community Pharmacy Medicines Management 
Project  
PRN When-Required 
COX Cyclo-oxygenase PSA Probabilistic Sensitivity Analysis 
CUA Cost-Utility Analysis  PTO Person Trade-Off  
DAA Dosage Administration Aid QALY Quality-Adjusted Life-Years  
DALY Disability-Adjusted Life-Year QOL Quality of Life 
DMMR Domiciliary Medication Management Review  QUM Quality Use of Medicines 
DRP Drug-Related Problem QUMCIT Quality Use of Medicines In The Community 
Implementation Trial 
DTP Drug-Therapy Problems  RACF Residential Aged Care Facility 
DVA Australian Government Department of 
Veterans' Affairs 
RCT Randomised Controlled Trial 
EQ-5D EuroQOL-5D RMMR Residential Medication Management Review 
GBD Global Burden of Disease SF-36 Short-Form 36 Health Survey 
GDP Gross Domestic Product  SG Standard Gamble  
GP General Practitioner SHPA Society of Hospital Pharmacists of Australia 
HMG-CoA Hydroxymethylglutamyl-Coenzyme A 
Reductase 
SMART Seniors Medication Assessment Research Trial  
HOMER Home-Based Medication Review Study  TTO Time Trade-Off  
ICER Incremental Cost-Effectiveness Ratio UK United Kingdom 
ICPC2-PLUS International Classification of Primary Care 
Version 2 Plus 
USA United States of America 
. An evaluation of pharmacist-conducted medication reviews in home-dwelling Australians 
Andrew Stafford BPharm(Hons) MPS AACPA . Page IX 
 
IMSANZ Internal Medicine Society of Australian and 
New Zealand 
VALMER The Value of Medication Reviews Study 
INR International Normalised Ratio WHO World Health Organisation 
IQR Interquartile Range WHO-
CHOICE 
World Health Organisation Choosing 
Interventions That Are Cost-Effective 
 
. An evaluation of pharmacist-conducted medication reviews in home-dwelling Australians 
Andrew Stafford BPharm(Hons) MPS AACPA . Page X 
 
Abstract 
Introduction: There is a high prevalence of drug-related problems (DRPs) in 
community-dwelling residents which results in increased morbidity, mortality and 
healthcare expenditure. The Australian government has reimbursed pharmacists to 
identify and prevent or resolve DRPs through Home Medicines Reviews (HMRs) in 
these patients since 2001. Funding for the HMR program was based on studies 
undertaken prior to its implementation that indicated HMRs would be cost-effective 
due to reductions in drug costs and health service utilisation. Since the introduction of 
the program, there has been limited Australian research into the economic outcomes 
of HMRs. Furthermore, the results of international studies have questioned the clinical 
and cost-effectiveness of pharmacist-led medication reviews. The overall aim of the 
research described in this thesis was to investigate the clinical and cost-effectiveness 
of HMRs. To achieve this aim, the following objectives were formulated and 
addressed: 
 to investigate novel methods for assessing the clinical and cost-effectiveness of 
HMRs; 
 to investigate the characteristics of the DRPs identified in HMRs, including the 
drugs and conditions involved, and the recommendations made to resolve or 
prevent DRPs; 
 to estimate the clinical effectiveness and cost-effectiveness of HMRs; and 
 to investigate potential avenues to optimise the clinical effectiveness and cost-
effectiveness of HMRs. 
Method: A methodology that used expert opinion to predict the outcomes of HMRs 
was developed, based on previous research of interventions undertaken in 
community pharmacies. The development of this methodology necessitated two 
studies to be undertaken whereby the healthcare system costs and quality of life 
effects of numerous common clinical conditions resulting from medication use were 
estimated using a combination of expert opinion and literature values. 
To evaluate HMRs, an observational cohort study was conducted across all states in 
Australia. Pharmacists accredited to perform HMRs submitted a random sample of 
HMRs that they had undertaken in 2008. Information from the HMR referral, report 
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and outcomes of the HMR were classified according to standardised systems and 
entered into an electronic database for analysis. A panel of experts reviewed a sample 
of the HMRs and estimated the clinical outcomes of the recommendations made in the 
HMRs. A cost-consequence and cost-utility analysis was performed to evaluate the 
cost-effectiveness of HMRs from an Australian government perspective.  
A sub-study was undertaken that investigated the relationship between cost-effective 
HMRs and factors that prior research suggested may influence the cost-effectiveness 
of HMRs. 
Results: A “consequences table” was developed whereby estimates of healthcare 
system costs and quality of life effects of 51 common clinical consequences were 
evaluated at three levels of severity. The estimates of these parameters appeared to be 
plausible and reasonable, and demonstrated moderate to high validity and reliability 
where testing was possible.  
Six hundred and sixty-one HMRs were submitted by one hundred and forty-nine 
pharmacists. The HMR reports documented 2323 DRPs, of which the most common 
were Condition not adequately treated (16.5% of DRPs), Therapy required (11.3%) and 
Toxicity evident (10.6%). The most common DRP was inadequate pain management 
which was identified in 118 (17.9%) patients. The drug groups most commonly 
involved in DRPs were antithrombotics, peptic ulcer and oesophageal reflux therapies, 
and lipid modifying agents.  
The pharmacists made 2727 recommendations to resolve the DRPs. The most 
frequently made recommendations included performing laboratory monitoring, 
commencing a new medication, or ceasing another. Information relating to the 
outcomes of the recommendations made to resolve the DRPs was available for 66% of 
the data (1801 recommendations). Of these recommendations, 1565 (87%) required 
the prescriber to act on the recommendations to implement them. Approximately 
three quarters of the DRPs documented in the HMRs were potentially resolved or 
managed. 
On average, each HMR was estimated to result in a saving to the health system of 
$85.79, which was insufficient to offset the cost of the HMR ($323.80). Savings 
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resulted from predicted reductions in health resource utilisation (general practitioner 
and specialist visits, medical investigations and hospitalisations (P<0.001)). A trend in 
reduced drug costs was also observed (P=0.070). Significant reductions in the risk of 
arrhythmias, confusion and myopathy were predicted to occur as a result of the HMRs 
(P<0.001).  Quality of life was estimated to improve minimally (0.001 QALYs per 
patient, P<0.001), and the cost per QALY gained (incremental cost-effectiveness ratio) 
was $177 566. Extensive sensitivity analysis was undertaken, which indicated 
minimal likelihood that HMRs were cost-effective using a threshold of $50 000 per 
QALY. A majority of the potential savings to the healthcare system occurred in a small 
number of HMRs. 
A sub-study of the factors associated with cost-effective HMRs identified that the 
pharmacists who had performed cost-effective HMRs had undertaken more 
continuing-education (P=0.006) and performed more HMRs in total (P=0.041) than 
the pharmacists who had not performed cost-effective HMRs. A greater proportion of 
HMR referrals that contained recent and relevant pathology/ laboratory data resulted 
in cost-effective HMRs compared to referrals that did not (P=0.03). 
Limitations resulting primarily from the methodology employed to assess the HMRs 
may have resulted in the study underestimating the cost-effectiveness of HMRs. Had a 
longer time horizon than 12-months been used, then greater cost savings to the 
healthcare system and improvements in quality of life would have been realised. The 
inclusion of other costs to the healthcare system not considered in the study also may 
have resulted in HMRs demonstrating greater cost-effectiveness.  
Conclusion: DRPs are frequently identified and reported in HMRs. However, the 
economic and clinical benefits of addressing most of them are minor in the 12 months 
following the HMR. Future research should focus on the identification of predictors of 
cost-effective HMRs and increasing the uptake of HMRs using these factors if funding 
for the program is to continue. 
 
. An evaluation of pharmacist-conducted medication reviews in home-dwelling Australians 
Andrew Stafford BPharm(Hons) MPS AACPA . Page XIII 
 
Table of Contents 
STATEMENTS AND DECLARATIONS ______________________________________________________ III 
Declaration of Originality _______________________________________________________________ III 
Authority of Access ______________________________________________________________________ III 
Statement of Ethical Conduct ___________________________________________________________ III 
ACKNOWLEDGEMENTS ___________________________________________________________________ V 
LIST OF PUBLICATIONS _________________________________________________________________ VI 
Peer-reviewed journal publications ____________________________________________________ VI 
Conference abstracts (oral) _____________________________________________________________ VI 
Conference abstracts (poster) __________________________________________________________ VI 
ABBREVIATIONS _____________________________________________________________________ VIII 
ABSTRACT ______________________________________________________________________________ X 
OVERVIEW _______________________________________________________________________ XXXVI 
THE NEED FOR MEDICATION REVIEWS ______________________________________________ XXXVI 
AIMS OF THESIS ______________________________________________________________________ XLI 
FUNDING NOTES ______________________________________________________________________ XLI 
STATEMENT OF CONTRIBUTION _______________________________________________________ XLI 
ETHICS APPROVAL ___________________________________________________________________ XLII 
CHAPTER 1 - BACKGROUND ____________________________________________________________ 1 
1.1 PHARMACEUTICAL CARE _____________________________________________________________ 1 
1.1.1 History and definition ______________________________________________________________ 1 
1.1.2 Drug-related problems _____________________________________________________________ 2 
1.1.3 Clinical and economic outcomes of pharmaceutical care ________________________ 9 
1.2 MEDICATION REVIEW _____________________________________________________________ 18 
. An evaluation of pharmacist-conducted medication reviews in home-dwelling Australians 
Andrew Stafford BPharm(Hons) MPS AACPA . Page XIV 
 
1.2.1 Definitions, types and objectives _________________________________________________ 18 
1.2.2 The Australian Home Medicines Review process _______________________________ 20 
1.3 EFFECTIVENESS AND COST-EFFECTIVENESS OF HMRS _______________________________ 26 
1.3.1 Australian QUM Evaluation Program Projects __________________________________ 28 
1.3.2 Recent Australian and international literature __________________________________ 43 
1.4 ECONOMIC EVALUATIONS __________________________________________________________ 71 
1.4.1 Overview of economic evaluations _______________________________________________ 71 
1.4.2 Types of economic evaluation ____________________________________________________ 72 
1.4.3 Definitions of cost-effectiveness __________________________________________________ 74 
1.5 CONCLUSIONS _____________________________________________________________________ 76 
1.6 AIMS AND OBJECTIVES _____________________________________________________________ 76 
CHAPTER 2 - GENERAL METHODS _____________________________________________________ 78 
2.1 OVERVIEW ________________________________________________________________________ 78 
2.1.1 Study design ________________________________________________________________________ 78 
2.1.2 Outcome measures ________________________________________________________________ 81 
2.1.3 Data collection _____________________________________________________________________ 81 
2.2 PHARMACIST CHARACTERISTICS ____________________________________________________ 84 
2.2.1 General demographics ____________________________________________________________ 84 
2.2.2 Clinical performance ______________________________________________________________ 85 
2.3 DRUG-RELATED PROBLEMS ________________________________________________________ 85 
2.3.1 DRP characteristics ________________________________________________________________ 86 
2.3.2 Recommendations and outcomes ________________________________________________ 88 
2.4 ECONOMIC PROTOCOL _____________________________________________________________ 89 
2.4.1 Research question and study perspective _______________________________________ 90 
2.4.2 Costs ________________________________________________________________________________ 90 
2.4.3 Time horizon _____________________________________________________________________ 102 
2.4.4 Sensitivity and uncertainty analysis ___________________________________________ 102 
2.4.5 Cost-utility analysis ______________________________________________________________ 105 
. An evaluation of pharmacist-conducted medication reviews in home-dwelling Australians 
Andrew Stafford BPharm(Hons) MPS AACPA . Page XV 
 
2.5 SAMPLE SIZE _____________________________________________________________________ 105 
2.6 EXPERT ASSESSMENT OF HMRS ___________________________________________________ 106 
2.6.1 Assessment of DRPs _____________________________________________________________ 106 
2.6.2 Selection of experts ______________________________________________________________ 107 
2.6.3 Collection of individual opinions _______________________________________________ 108 
2.6.4 Consensus of opinion ____________________________________________________________ 111 
2.7 STATISTICAL ANALYSIS ___________________________________________________________ 112 
CHAPTER 3 - COSTING HEALTH RESOURCE UTILISATION _____________________________ 114 
3.1 INTRODUCTION ___________________________________________________________________ 114 
3.1.1 Creation of the list of consequences ____________________________________________ 114 
3.1.2 Parameters describing each consequence _____________________________________ 118 
3.2 METHODS ________________________________________________________________________ 120 
3.2.1 Hospitalisation ___________________________________________________________________ 120 
3.2.2 Non-hospitalisation treatment _________________________________________________ 121 
3.2.3 Analysis ___________________________________________________________________________ 124 
3.3 RESULTS _________________________________________________________________________ 126 
3.3.1 Duration and cost of hospitalisation ___________________________________________ 126 
3.3.2 Duration of illness and cost of non-hospitalisation treatment _______________ 127 
3.3.3 Total cost and duration __________________________________________________________ 152 
3.3.4 Distributions fitted ______________________________________________________________ 155 
3.3.5 Validity ___________________________________________________________________________ 155 
3.4 DISCUSSION ______________________________________________________________________ 161 
CHAPTER 4 - MEASURING QUALITY OF LIFE _________________________________________ 167 
4.1 INTRODUCTION ___________________________________________________________________ 167 
4.2 METHODS ________________________________________________________________________ 169 
4.2.1 Utility sets ________________________________________________________________________ 169 
4.2.2 Alternative sources of utilities __________________________________________________ 172 
. An evaluation of pharmacist-conducted medication reviews in home-dwelling Australians 
Andrew Stafford BPharm(Hons) MPS AACPA . Page XVI 
 
4.2.3 Participants ______________________________________________________________________ 178 
4.2.4 Number of assessors ____________________________________________________________ 179 
4.2.5 Data collection ___________________________________________________________________ 179 
4.2.6 Reliability and validity of the utilities __________________________________________ 180 
4.3 RESULTS _________________________________________________________________________ 182 
4.3.1 Overview _________________________________________________________________________ 182 
4.3.2 Utilities assigned from reference sets __________________________________________ 182 
4.3.3 Utilities developed using EQ-5D ________________________________________________ 190 
4.3.4 Distributions fitted ______________________________________________________________ 200 
4.4 DISCUSSION ______________________________________________________________________ 200 
4.5 CONCLUSION _____________________________________________________________________ 203 
CHAPTER 5 - RESULTS OF THE VALMER STUDY: CHARACTERISTICS OF PHARMACISTS, 
PATIENTS AND DRUG-RELATED PROBLEMS __________________________________________ 204 
5.1 OVERVIEW _______________________________________________________________________ 204 
5.2 PARTICIPATING PHARMACISTS ____________________________________________________ 206 
5.2.1 General pharmacist demographics _____________________________________________ 206 
5.2.2 Clinical performance ____________________________________________________________ 209 
5.2.3 Interaction with General Practitioners _________________________________________ 212 
5.2.4 Focus on particular HMR-related tasks ________________________________________ 213 
5.2.5 Use of medication-review software ____________________________________________ 214 
5.2.6 Effect of the DVA Dosage Administration Aid Program _______________________ 215 
5.2.7 Time to perform HMRs __________________________________________________________ 217 
5.3 PATIENT CHARACTERISTICS _______________________________________________________ 218 
5.3.1 Diagnosed conditions ____________________________________________________________ 220 
5.3.2 Medications taken _______________________________________________________________ 222 
5.3.3 Indication for HMR referral _____________________________________________________ 224 
5.4 DRUG-RELATED PROBLEMS IDENTIFIED ___________________________________________ 225 
5.4.1 Type of DRPs _____________________________________________________________________ 226 
5.4.2 Medical conditions associated with DRPs _____________________________________ 228 
. An evaluation of pharmacist-conducted medication reviews in home-dwelling Australians 
Andrew Stafford BPharm(Hons) MPS AACPA . Page XVII 
 
5.4.3 Drugs associated with DRPs ____________________________________________________ 234 
5.4.4 Overall DRP characteristics _____________________________________________________ 250 
5.4.5 Recommendations made ________________________________________________________ 252 
5.4.6 Uptake of recommendations ____________________________________________________ 259 
5.5 SUMMARY OF RESULTS ____________________________________________________________ 272 
CHAPTER 6 - RESULTS OF THE VALMER STUDY: POTENTIAL CLINICAL AND ECONOMIC 
OUTCOMES OF HMRS _______________________________________________________________ 274 
6.1 INTRODUCTION ___________________________________________________________________ 274 
6.2 DRUG COST ANALYSIS _____________________________________________________________ 274 
6.2.1 Drug costs before HMR __________________________________________________________ 275 
6.2.2 Drug costs after HMR ____________________________________________________________ 277 
6.3 COST-CONSEQUENCE ANALYSIS - CLINICAL OUTCOMES AND ASSOCIATED COSTS ______ 287 
6.3.1 Sampling considerations ________________________________________________________ 287 
6.3.2 Characteristics of the sample ___________________________________________________ 289 
6.3.3 Preliminary analysis of results of expert panel assessment __________________ 297 
6.3.4 Health resource costs and quality of life _______________________________________ 310 
6.4 COST-UTILITY AND SCENARIO ANALYSIS - DATASET OF 60 HMRS ASSESSED BY EVERY 
EXPERT ______________________________________________________________________________ 336 
6.4.1 Overview _________________________________________________________________________ 336 
6.4.2 Baseline scenario ________________________________________________________________ 337 
6.4.3 HMR cost _________________________________________________________________________ 340 
6.4.4 Attribution to the pharmacist ___________________________________________________ 344 
6.4.5 Uptake of recommendations ____________________________________________________ 346 
6.4.6 Best case - inclusion of DRPs not assessed by experts ________________________ 350 
6.4.7 Worst case ________________________________________________________________________ 354 
6.5 SUMMARY OF RESULTS ____________________________________________________________ 355 
CHAPTER 7 - DISCUSSION AND CONCLUSIONS OF THE VALMER STUDY _____________ 358 
7.1 DRUG-RELATED PROBLEMS _______________________________________________________ 358 
. An evaluation of pharmacist-conducted medication reviews in home-dwelling Australians 
Andrew Stafford BPharm(Hons) MPS AACPA . Page XVIII 
 
7.2 CLINICAL AND ECONOMIC OUTCOMES ______________________________________________ 362 
7.2.1 Clinical outcomes ________________________________________________________________ 362 
7.2.2 Economic analysis _______________________________________________________________ 364 
7.3 LIMITATIONS _____________________________________________________________________ 373 
7.3.1 Study design ______________________________________________________________________ 374 
7.3.2 Methodological issues ___________________________________________________________ 380 
7.4 CONCLUSIONS ____________________________________________________________________ 385 
CHAPTER 8 - FACTORS RELATED TO THE COST-EFFECTIVENESS OF HMRS ___________ 386 
8.1 INTRODUCTION ___________________________________________________________________ 386 
8.2 METHODS ________________________________________________________________________ 388 
8.3 RESULTS _________________________________________________________________________ 393 
8.3.1 Patient factors ____________________________________________________________________ 393 
8.3.2 Pharmacist factors _______________________________________________________________ 395 
8.3.3 Process factors ___________________________________________________________________ 398 
8.4 DISCUSSION ______________________________________________________________________ 400 
8.4.1 Patient factors ____________________________________________________________________ 400 
8.4.2 Pharmacist factors _______________________________________________________________ 401 
8.4.3 Process factors ___________________________________________________________________ 402 
8.4.4 Limitations _______________________________________________________________________ 403 
8.5 CONCLUSIONS ____________________________________________________________________ 405 
CHAPTER 9 - CONCLUSIONS _________________________________________________________ 406 
REFERENCES ________________________________________________________________________ 411 
APPENDICES ________________________________________________________________________ 438 
APPENDIX I - ETHICS APPROVAL ______________________________________________________ 439 
APPENDIX II - PHARMACIST CONSENT FORM ___________________________________________ 444 
. An evaluation of pharmacist-conducted medication reviews in home-dwelling Australians 
Andrew Stafford BPharm(Hons) MPS AACPA . Page XIX 
 
APPENDIX III - VALMER STUDY OUTCOMES SUMMARY FORM _________________________ 445 
APPENDIX IV - PROJECT PROMOTION (PRINT MEDIA) __________________________________ 447 
APPENDIX V - PHARMACY GUILD OF AUSTRALIA MEDIA RELEASE _______________________ 448 
APPENDIX VI - VALMER PROJECT NEWSLETTERS _____________________________________ 449 
APPENDIX VII - VALMER STUDY PHARMACIST SURVEY ________________________________ 454 
APPENDIX VIII - DOCUMENT CLASSIFICATION SYSTEM SCOPE NOTES _________________ 467 
APPENDIX IX - METHODOLOGICAL FRAMEWORK PAPER BY STAFFORD ET AL. ____________ 509 
APPENDIX X - ADVERTISEMENT FOR RECRUITMENT OF SPECIALISTS FOR HMR ASSESSMENT
 517 
APPENDIX XI - TRAINING MANUAL FOR HMR ASSESSMENT _____________________________ 518 
APPENDIX XII - TENNI’S CONSEQUENCES TABLE _______________________________________ 537 
APPENDIX XIII ADVERTISEMENT TO RECRUIT GPS FOR CONSEQUENCES STUDY __________ 550 
APPENDIX XIV - QUESTIONNAIRE FOR GPS WHO PARTICIPATED IN CONSEQUENCES STUDY
 551 
APPENDIX XV - CONSEQUENCES STUDY PARTICIPANT INFORMATION BOOKLET __________ 555 
APPENDIX XVI - CONSEQUENCES STUDY RESULTS - PATHOLOGY AND LABORATORY 
INVESTIGATIONS ______________________________________________________________________ 558 
APPENDIX XVII - CONSEQUENCES TABLE ______________________________________________ 571 
APPENDIX XVIII - QUALITY OF LIFE STUDY PARTICIPANT INFORMATION BOOKLET _______ 598 
APPENDIX XIX - SUPPLEMENTARY DRP DATA TABLES _________________________________ 601 
APPENDIX XX - EXAMPLES OF REFERRALS ACCORDING TO DEFINITIONS USED FOR 
STRATIFICATION ______________________________________________________________________ 624 
APPENDIX XXI - EXAMPLE CALCULATION OF POTENTIAL ECONOMIC VALUE ______________ 633 
Introduction ____________________________________________________________________________ 633 
DRPs assessed __________________________________________________________________________ 635 
Calculation of potential economic value _____________________________________________ 635 
. An evaluation of pharmacist-conducted medication reviews in home-dwelling Australians 
Andrew Stafford BPharm(Hons) MPS AACPA . Page XX 
 
Calculation of potential clinical outcomes ___________________________________________ 645 
APPENDIX XXII - SUPPLEMENTARY HMR COSTING DATA ______________________________ 647 
APPENDIX XXIII - RESAMPLED INCREMENTAL COST-EFFECTIVENESS RATIOS ____________ 679 
APPENDIX XXIV - COMMENT FROM ACCREDITED PHARMACIST REGARDING PROVISION OF 
PATHOLOGY/ LABORATORY DATA IN HMR REFERRALS _________________________________ 689 
 
  
